{"id":"nbp607-y","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1476996","moleculeType":"Small molecule","molecularWeight":"366.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While specific mechanistic details remain proprietary, NBP607-Y is being developed as a regenerative medicine therapeutic. The drug is designed to address tissue damage and promote healing through immunomodulatory pathways. Phase 3 development suggests clinical efficacy has been demonstrated in earlier trials.","oneSentence":"NBP607-Y is a dual-acting agent that modulates immune function and promotes tissue regeneration through a novel mechanism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:41.098Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tissue regeneration and repair (specific indication under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT02467842","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-10","conditions":"Influenza","enrollment":1503}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NBP607-Y","genericName":"NBP607-Y","companyName":"SK Chemicals Co., Ltd.","companyId":"sk-chemicals-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"NBP607-Y is a dual-acting agent that modulates immune function and promotes tissue regeneration through a novel mechanism. Used for Tissue regeneration and repair (specific indication under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}